A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors

被引：0
|
作者：
Papadopoulos, K. [1 ]
Tolcher, A. [1 ]
Kittaneh, M. [2 ]
Patniak, A. [1 ]
Rasco, D. [1 ]
Chambers, G. [1 ]
Newth, G. [2 ]
Savage, R. [3 ]
Hall, T. [3 ]
Schwartz, B. [3 ]
Kazakin, J. [3 ]
LoRusso, P. [2 ]
机构：
[1] South Texas Accelerated Res Therapeut, Med Oncol, San Antonio, TX USA
[2] Karmanos Canc Inst, Ctr Translat Therapeut, Detroit, MI USA
[3] ArQule Inc, Clin Dev, Woburn, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70515-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [41] Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients (pts) with advanced solid tumors (ASTs).
    Vogelzang, Nicholas J.
    George, Ben
    Ashenbramer, Nissa
    Edenfield, William J.
    Richards, Donald
    Gross, Mitchell E.
    Fine, Gil D.
    Martinez, Pablo
    CANCER RESEARCH, 2022, 82 (12)
  • [42] First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
    Lieu, C.
    Lenz, H. J.
    Kim, K. P.
    Sung, M. J.
    Kim, U-I.
    Meng, X.
    Benson, A. B., III
    ANNALS OF ONCOLOGY, 2024, 35 : S504 - S504
  • [43] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [44] A PHASE I DOSE-ESCALATION STUDY OF EMD 1214063, AN ORAL SELECTIVE CMET INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Naing, A.
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Tsimberidou, A. M.
    Wheler, J. J.
    Janku, F.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 21 - 21
  • [45] Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
    Sequist, Lecia V.
    Cassier, Phillippe
    Varga, Andrea
    Tabernero, Josep
    Schellens, Jan H.
    Delord, Jean-Pierre
    LoRusso, Patricia
    Camidge, D. Ross
    Hidalgo Medina, Manuel
    Schuler, Martin
    Campone, Mario
    Tian, G. Gary
    Wong, Steven
    Corral, Jesus
    Isaacs, Randi
    Sen, Suman K.
    Porta, Diana Graus
    Kulkarni, Swarupa G.
    Lefebvre, Caroline
    Wolf, Juergen
    CANCER RESEARCH, 2014, 74 (19)
  • [46] First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors
    Carducci, Michael Anthony
    Shaheen, Montaser F.
    Paller, Channing Judith
    Bauman, Julie E.
    Azad, Nilofer Saba
    Shubhakar, Poornima
    Tang, Rui
    Stroh, Mark
    Friberg, Gregory R.
    Verschraegen, Claire F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.
    Borazanci, Erkut Hasan
    Janku, Filip
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Sen, Shiraj
    Fu, Siqing
    Wheeler, Catherine A.
    Wages, David S.
    Matsumoto, Takeshi
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Madden, Timothy
    Johansen, Mary
    Maier, Gary
    Cheung, Kin
    Korn, Ron
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael
    Yung-Jue Bang
    Young Suk Park
    Yoon-Koo Kang
    Tae Min Kim
    Oday Hamid
    Donald Thornton
    Sonya C. Tate
    Eyas Raddad
    Jeanne Tie
    Targeted Oncology, 2017, 12 : 463 - 474
  • [49] A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
    Hong, David S.
    Rosen, Peter
    Lockhart, A. Craig
    Fu, Siqing
    Janku, Filip
    Kurzrock, Razelle
    Khan, Rabia
    Amore, Benny
    Caudillo, Isaac
    Deng, Hongjie
    Hwang, Yuying C.
    Loberg, Robert
    Ngarmchamnanrith, Gataree
    Beaupre, Darrin M.
    Lee, Peter
    ONCOTARGET, 2015, 6 (21) : 18693 - 18706
  • [50] A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors
    Deutsch, Eric
    Moyal, Elizabeth Cohen-Jonathan
    Gregorc, Vanesa
    Zucali, Paolo Andrea
    Menard, Jean
    Soria, Jean-Charles
    Kloos, Ioana
    Hsu, Jeff
    Luan, Ying
    Liu, Emily
    Vezan, Remus
    Graef, Thorsten
    Rivera, Sofia
    ONCOTARGET, 2017, 8 (34) : 56199 - 56209
12345